Highmark First to Cover AppliedVR's Flagship VR Device for Chronic Low Back Pain Treatment
Highmark First to Cover AppliedVR's Flagship VR Device for Chronic Low Back Pain Treatment
FDA-authorized RelieVRx now a covered treatment for Highmark's commercial members experiencing chronic low back pain (CLBP)
美國食品藥品管理局授權的RelieVRX現在是Highmark商業會員患有慢性腰痛(CLBP)的承保範圍內的治療方案
PITTSBURGH, Sept. 9, 2024 /PRNewswire/ -- AppliedVR, a pioneer in immersive therapeutics (ITx) advancing virtual reality-based medicine, announced today that Highmark, a leading commercial health insurance plan based in Pittsburgh, PA, will now cover RelieVRx, AppliedVR's FDA-authorized device for chronic low back pain (CLBP). This landmark decision makes RelieVRx accessible as a covered therapeutic to more than four million Highmark members across its commercial lines of business.
匹茲堡,2024 年 9 月 9 日 /PRNewswire/-- AppliedVR是推進基於虛擬現實的醫學的沉浸式療法(ITx)的先驅,今天宣佈,總部位於賓夕法尼亞州匹茲堡的領先商業健康保險計劃Highmark現在將承保 RelieVRX,AppliedVR 經美國食品藥品管理局批准的慢性下背痛 (CLBP) 設備。這一具有里程碑意義的決定使RelieVRX作爲承保療法可供其商業業務領域的400多萬Highmark會員使用。
RelieVRx offers a fully immersive virtual reality (VR) experience designed to empower individuals with skills for managing CLBP. It serves as a cost-effective, non-pharmacologic adjunctive therapy clinically proven to significantly reduce pain intensity and interference across sociodemographic groups.
RelieVRX 提供完全身臨其境的虛擬現實 (VR) 體驗,旨在讓個人掌握管理 CLBP 的技能。它是一種經濟實惠的非藥物輔助療法,經臨床證明可顯著降低疼痛強度和干擾 跨社會人口群體。
Patients using RelieVRx undergo a 56-session, multimodal program, featuring daily VR sessions that address the bio-psycho-social aspects of pain. RelieVRx is self-administered by patients in their own homes and has an easy-to-use interface. In clinical testing, RelieVRx usability ratings were consistently high (A+), which was largely consistent across subgroups.1
使用RelievRX的患者將接受56次療程的多模式計劃,其中包括每天的虛擬現實療程,以解決疼痛的生物心理和社會方面。RelieVrx 由患者在家中自行管理,界面易於使用。在臨床測試中,RelievRX的可用性評級一直很高(A+),各子組之間基本一致。1
Highmark's decision to cover RelieVRx follows a thorough evaluation of AppliedVR's extensive clinical studies, including a large study with more than 1,000 participants that found RelieVRx can have a clinically meaningful impact on reducing pain intensity and interference. Eligible commercial members aged 18 and older diagnosed with moderate to severe CLBP can now obtain a prescription for RelieVRx from their healthcare provider without prior authorization.
Highmark之所以決定爲RelieVRX提供保險,是因爲對AppliedVR的廣泛臨床研究進行了全面評估,其中包括 大型研究 超過1,000名參與者發現RelievRX可以對減輕疼痛強度和干擾產生臨床上有意義的影響。18歲及以上被診斷患有中度至重度CLBP的符合條件的商業會員現在無需事先授權即可從其醫療保健提供者處獲得RelieVRX的處方。
"We are committed to leveraging technology to enhance health outcomes while reducing costs," said Matt Fickie, Senior Medical Director for Highmark. "RelieVRx from AppliedVR provides our members suffering from chronic low back pain a scientifically backed, in-home immersive non-opioid treatment option."
Highmark高級醫學董事馬特·菲基說:「我們致力於利用技術來改善健康狀況,同時降低成本。」「AppliedVR的RelieVRX爲我們患有慢性腰痛的會員提供了有科學依據的居家沉浸式非阿片類藥物治療選擇。」
Chronic pain imposes a significant economic burden on the U.S., estimated at $635 billion annually, and is a primary driver of the opioid crisis. More than 72 million Americans suffer from CLBP, which also is a leading cause of disability.
慢性疼痛給美國帶來了巨大的經濟負擔,估計爲 每年6350億美元,也是阿片類藥物危機的主要驅動力。超過 7200萬美國人 患有 CLBP,這也是 主要原因 殘障人士。
"Every individual battling CLBP deserves access to noninvasive, drug-free options that empower them to self-manage their pain. Highmark's forward-thinking approach recognizes the promise of immersive therapeutics, and we are grateful for their collaboration," said Matthew Stoudt, Co-founder and CEO of AppliedVR. "RelieVRx is based on decades of clinical evidence demonstrating the transformative potential of immersive therapeutics to reshape the body's response to pain, and we are committed to building an even greater body of evidence that continues to set the industry standard."
「每個與CLBP作鬥爭的人都應該獲得非侵入性、無藥物的選擇,使他們能夠自我管理自己的疼痛。Highmark的前瞻性方法認可了沉浸式療法的前景,我們感謝他們的合作。」 AppliedVR聯合創始人兼首席執行官馬修·斯托特說。「RelievRX基於數十年的臨床證據,這些證據表明沉浸式療法具有重塑人體對疼痛反應的變革潛力,我們致力於建立更多的證據,繼續設定行業標準。」
While Highmark becomes the first commercial health plan to adopt coverage for RelieVRx, AppliedVR has experienced significant momentum with payers over the last year:
儘管Highmark成爲第一個爲RelieVRX提供保險的商業健康計劃,但AppliedVR在過去一年中在付款人中表現強勁:
- RelieVRx previously received a unique code and final pricing determination from the Centers for Medicare and Medicaid Services (CMS).
- RelieVRx was added to the Department of Veterans Affairs' Federal Supply Schedule (FSS), Defense Logistics Agency's Electronic Catalogue for Medical Supply Chain (ECAT), and the Department of Defense's Distribution and Pricing Agreement (DAPA), allowing government customers to make streamlined purchases. RelieVRx is now available nationwide and is currently used in more than 40 Veterans Affairs (VA) sites.
- VA Immersive, a division of Veterans Health Administration (VHA), extended its contract with AppliedVR to facilitate accelerated uptake.
- AppliedVR also recently expanded into the Worker's Compensation market.
- 之前收到的 RelieVRX 獨一無二的代碼 以及醫療保險和醫療補助服務中心(CMS)的最終定價決定。
- RelieVRX 已添加 退伍軍人事務部的聯邦供應計劃(FSS)、國防後勤局的醫療供應鏈電子目錄(ECAT)和國防部的分銷和定價協議(DAPA),允許政府客戶簡化採購。RelievRX現已在全國範圍內上市,目前在40多個退伍軍人事務部(VA)網站上使用。
- 退伍軍人健康管理局(VHA)下屬的 VA Immersive 延長了合同 使用 AppliedVR 來促進加速吸收。
- AppliedVR 最近還擴展到 工人補償市場。
About AppliedVR
AppliedVR is creating a new reality in healthcare. AVR is pioneering immersive therapeutics (ITx), a new category of medicine, to treat intractable health conditions that affect millions of people worldwide. Today, AppliedVR's treatments represent a robust approach to chronic lower back pain (CLBP) that empowers patients with an intuitive device they can self-manage at home. For more information, visit .
關於 AppliedVR
AppliedVR 正在醫療保健領域創造一個新的現實。AVR是沉浸式療法(iTx)的先驅,這是一種新的藥物,用於治療影響全球數百萬人的棘手健康狀況。如今,AppliedVR的治療代表了一種治療慢性腰痛(CLBP)的強大方法,爲患者提供了一種可以在家中自我管理的直觀設備。欲了解更多信息,請訪問 。
1 Research indicated some slight differences among race/ethnicity.
1 研究表明,種族/民族之間存在細微差別。
Contacts
Sam Moore
[email protected]
聯繫人
山姆·摩爾
[電子郵件保護]
SOURCE AppliedVR
來源 AppliedVR
譯文內容由第三人軟體翻譯。